Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia.
Intravenous (IV) administration of anti-D in patients with autoimmune thrombocytopenia (AITP) may result in severe hemolysis and even death. Over a 3-year period, we gave anti-D only subcutaneously (SC), and none of our patients have developed any acute adverse reaction. Most importantly, SC delivery of anti-D produces largely the same beneficial effect as obtained by IV anti-D. We recommend replacement of IV administration of anti-D by SC administration in AITP.
Meyer
O
O
Institut für Transfusionsmedizin, Charité, Universitätsmedizin, Berlin, Germany.
Kiesewetter
H
H
Hermsen
M
M
Petriedes
P
P
Rose
M
M
Seibt
H
H
Salama
A
A
D000328:Adult; D002648:Child; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007518:Isoantibodies / Q000008:administration & dosage*; D008297:Male; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000188:drug therapy*; D018029:Rho(D) Immune Globulin; D016896:Treatment Outcome
D007518:Isoantibodies; C061961:RHO(D) antibody; D018029:Rho(D) Immune Globulin